Cargando…
Experience and Expectations of Ovarian Cancer Patients in Australia
Some of the most significant advances in ovarian cancer treatment have been those that result in improvements in progression-free survival (PFS); however there is little research to understand the value that patients place on accessing therapies that result in PFS as a clinical outcome related to su...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5863331/ https://www.ncbi.nlm.nih.gov/pubmed/29707001 http://dx.doi.org/10.1155/2018/7863520 |
_version_ | 1783308364703334400 |
---|---|
author | Holliday, Catherine M. Morte, Maria Byrne, Josephine M. Holliday, Anne T. |
author_facet | Holliday, Catherine M. Morte, Maria Byrne, Josephine M. Holliday, Anne T. |
author_sort | Holliday, Catherine M. |
collection | PubMed |
description | Some of the most significant advances in ovarian cancer treatment have been those that result in improvements in progression-free survival (PFS); however there is little research to understand the value that patients place on accessing therapies that result in PFS as a clinical outcome related to survivorship. This study therefore aimed to understand the experience and expectations of women with ovarian cancer in Australia in relation to quality of life (QoL) and treatment options. An online survey collected demographic information and 13 investigator-derived structured interview questions were developed to understand the experience of women with ovarian cancer, their understanding of terminology associated with their condition, and expectations of future treatment. This study demonstrated that ovarian cancer patients equate PFS with being in remission and that patients expect QoL during that time to be good to excellent. Women in this study described excellent QoL as feeling positive and happy and not worrying about cancer, feeling fit and healthy without side effects, and being able to live life as they did before their diagnosis, including the absence of fear of progression or recurrence. It is therefore suggested that there is a positive relationship between PFS and QoL. While it is difficult to quantify QoL and further research is needed, the results of this study suggest that the minimum time that women with ovarian cancer expect in relation to treatments that result in PFS is approximately six months. In the absence of this information, decision-makers are left to make assumptions about the value women place on access to therapeutics that increase PFS, which for this type of cancer is an important aspect of survivorship. |
format | Online Article Text |
id | pubmed-5863331 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Hindawi |
record_format | MEDLINE/PubMed |
spelling | pubmed-58633312018-04-29 Experience and Expectations of Ovarian Cancer Patients in Australia Holliday, Catherine M. Morte, Maria Byrne, Josephine M. Holliday, Anne T. J Oncol Research Article Some of the most significant advances in ovarian cancer treatment have been those that result in improvements in progression-free survival (PFS); however there is little research to understand the value that patients place on accessing therapies that result in PFS as a clinical outcome related to survivorship. This study therefore aimed to understand the experience and expectations of women with ovarian cancer in Australia in relation to quality of life (QoL) and treatment options. An online survey collected demographic information and 13 investigator-derived structured interview questions were developed to understand the experience of women with ovarian cancer, their understanding of terminology associated with their condition, and expectations of future treatment. This study demonstrated that ovarian cancer patients equate PFS with being in remission and that patients expect QoL during that time to be good to excellent. Women in this study described excellent QoL as feeling positive and happy and not worrying about cancer, feeling fit and healthy without side effects, and being able to live life as they did before their diagnosis, including the absence of fear of progression or recurrence. It is therefore suggested that there is a positive relationship between PFS and QoL. While it is difficult to quantify QoL and further research is needed, the results of this study suggest that the minimum time that women with ovarian cancer expect in relation to treatments that result in PFS is approximately six months. In the absence of this information, decision-makers are left to make assumptions about the value women place on access to therapeutics that increase PFS, which for this type of cancer is an important aspect of survivorship. Hindawi 2018-03-07 /pmc/articles/PMC5863331/ /pubmed/29707001 http://dx.doi.org/10.1155/2018/7863520 Text en Copyright © 2018 Catherine M. Holliday et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Holliday, Catherine M. Morte, Maria Byrne, Josephine M. Holliday, Anne T. Experience and Expectations of Ovarian Cancer Patients in Australia |
title | Experience and Expectations of Ovarian Cancer Patients in Australia |
title_full | Experience and Expectations of Ovarian Cancer Patients in Australia |
title_fullStr | Experience and Expectations of Ovarian Cancer Patients in Australia |
title_full_unstemmed | Experience and Expectations of Ovarian Cancer Patients in Australia |
title_short | Experience and Expectations of Ovarian Cancer Patients in Australia |
title_sort | experience and expectations of ovarian cancer patients in australia |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5863331/ https://www.ncbi.nlm.nih.gov/pubmed/29707001 http://dx.doi.org/10.1155/2018/7863520 |
work_keys_str_mv | AT hollidaycatherinem experienceandexpectationsofovariancancerpatientsinaustralia AT mortemaria experienceandexpectationsofovariancancerpatientsinaustralia AT byrnejosephinem experienceandexpectationsofovariancancerpatientsinaustralia AT hollidayannet experienceandexpectationsofovariancancerpatientsinaustralia |